21-208

STUDY BASICS

Are you post-menopausal, with ductal carcinoma in situ (DCIS) and expect to receive standard treatment for your DCIS? You may be eligible for a research study evaluate how immune systems (the part of your body that fights diseases) responds to an experimental treatment versus standard of care treatment. Compensation is provided.

STUDY PURPOSE

The main goal of this research study is to evaluate how immune systems (the part of your body that fights diseases) responds to an experimental treatment versus standard of care treatment. 

COULD THIS STUDY BE RIGHT FOR YOU?

• woman 18 years of age or older
• are post-menopausal 
• have ductal carcinoma in situ (DCIS) and expect to receive standard treatment for their DCIS. 

WHAT PARTICIPANTS CAN EXPECT

You will be randomized to one of 2 groups:

An experimental group that consists of:

1. A vaccine made of a MUC1 peptide and poly-ICLC together with,
2. Standard treatment for breast DCIS that includes surgery with or without radiation, and
3. An estrogen blocking drug. Your DCIS expresses the estrogen receptor, which means that estrogen blocking drugs that prevent estrogen from reaching your DCIS may help decrease its growth.

OR

A control group that will get:

1. Standard treatment for breast DCIS that includes surgery with or without radiation, and
2. An estrogen blocking drug. Your DCIS expresses the estrogen receptor, which means that estrogen blocking drugs that prevent estrogen from reaching your DCIS may help decrease its growth. The difference between the two groups is receiving the vaccine. You have a 66% chance of being assigned to the vaccine group.